Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 8;23(1):314.
doi: 10.1186/s12935-023-03156-6.

Technical comparison of Abbott's UroVysion® and Biocare's CytoFISH urine fluorescence in situ hybridization (FISH) assays

Tammy Anderson  1 , Sharon Hartman  2 , William Dunn  1 , Harvey Bellin  1 , Thomas W Ehlers  3 , Sarah Groen  3 , Jason A Ramos  3
Affiliations

Technical comparison of Abbott's UroVysion® and Biocare's CytoFISH urine fluorescence in situ hybridization (FISH) assays

Tammy Anderson et al. Cancer Cell Int. .

Abstract

Background: This study aims to compare the technical performance of Abbott's UroVysion and Biocare's CytoFISH urine cytology probe panel and position the CytoFISH probe panel as an alternative to UroVysion. The CytoFISH probe panel was developed based on clinically sensitive chromosomes found to be amplified in bladder cancers, as well as a locus-specific probe also seen to be amplified in bladder tumors. After extensive testing comparing CytoFISH to UroVysion, we present here our findings for the two assays.

Materials and methods: A total of 216 cases representing a mix of male (ages 36-99) and female (ages 46-91) patients were assayed with both probe sets. The CytoFISH and UroVysion probe panels were tested in accordance with the UroVysion procedure, as outlined in the manufacturer's supplied package insert with the following exception: the probe volume used was 3µL for UroVysion and 5µL for CytoFISH.

Results: The scoring used for the CytoFISH and UroVysion assays revealed a 95% concordance, suggesting that Biocare's CytoFISH Test has at least the same clinical sensitivity and specificity as claimed by the Abbott UroVysion Kit. We found that the CytoFISH 5p15.2 locus-specific probe was easier to score than UroVysion's 9p21 deletion.

Conclusion: The high rate of concordance between the two assays suggests that Biocare's CytoFISH assay is a robust alternative to Abbott's UroVysion in the diagnosis and monitoring of bladder carcinoma.

Keywords: 5p15.2; 9p21; Aneuploidy; Bladder cancer; FISH; Urinary.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Examples of (A) normal urothelial cells, (B) urothelial cells with chromosomal gains and 5p15.2 amplifications, and (C) suspicious cases
Fig. 2
Fig. 2
Number of patient cases scored by CytoFISH Test or UroVysion Kit. For CytoFISH, the cases for each scoring category are represented by black bars. For UroVysion, the cases for each scoring category are represented by gray bars
See this image and copyright information in PMC

References

    1. Ozery-Flato M, Linhart C, Trakhtenbrot L, et al. Large-scale analysis of chromosomal aberrations in cancer karyotypes reveals two distinct paths to aneuploidy. Genome Biol. 2011;12(6):R61. doi: 10.1186/gb-2011-12-6-r61. - DOI - PMC - PubMed
    1. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay) Adv Anat Pathol. 2008;15(5):279–86. doi: 10.1097/PAP.0b013e3181832320. - DOI - PubMed
    1. US Food and Drug Administration., Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health. 510(k) Summary: Safety and Effectiveness Information for the UroVysion™ Bladder Cancer Recurrence Kit approval letter, December 19, 2003. Available from http://www.accessdata.fda.gov/cdrh_docs/pdf3/k033982.pdf. Accessed September 23, 2016.
    1. Zheng M, Simon R, Mirlacher M, et al. TRIO amplification and abundant mRNA expression is associated with invasive Tumor growth and rapid Tumor cell proliferation in urinary Bladder cancer. Am J Pathol. 2004;165(1):63–9. doi: 10.1016/S0002-9440(10)63275-0. - DOI - PMC - PubMed
    1. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of Bladder cancer. J Urol. 1994;151(3):545–60. doi: 10.1016/S0022-5347(17)35014-0. - DOI - PubMed

LinkOut - more resources